| Summary of segment net loss including significant segment expenses |
The table below is a summary of segment net loss including significant segment expenses for the three and six months ended June 30, 2026 and 2025 (in thousands): | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | Revenue: | | | | | | | | | | | | Product revenue, net | $ | 25,078 | | $ | 2,137 | | $ | 43,749 | | $ | 2,137 | Sale of COPIKTRA license and related assets | | 15,000 | | | — | | | 15,000 | | | — | Expenses: | | | | | | | | | | | | Cost of sales - product | | 3,762 | | | 318 | | | 6,532 | | | 318 | Cost of sales - intangible amortization | | 279 | | | 128 | | | 559 | | | 128 | Research and development expenses(1) | | 40,050 | | | 23,979 | | | 77,422 | | | 52,532 | Commercial expenses(1) | | 11,899 | | | 8,364 | | | 21,775 | | | 12,417 | Medical affairs expenses(1) | | 4,468 | | | 2,234 | | | 7,576 | | | 4,459 | General and administrative expenses(1) | | 8,537 | | | 7,475 | | | 15,812 | | | 15,140 | Stock-based compensation expense | | 3,430 | | | 3,413 | | | 5,476 | | | 5,084 | Depreciation expense | | — | | | — | | | — | | | 10 | Interest income | | (1,108) | | | (822) | | | (2,405) | | | (1,782) | Interest expense | | 360 | | | 212 | | | 743 | | | 404 | Loss on debt extinguishment | | — | | | — | | | — | | | 1,826 | Change in fair value of warrant liability | | — | | | (20,320) | | | (9,323) | | | (17,904) | Change in fair value of Notes | | 1,843 | | | 2,990 | | | 3,714 | | | 7,405 | Other segment items(2) | | 415 | | | 100 | | | 1,316 | | | 137 | Income tax expense | | 816 | | | — | | | 816 | | | — | Net loss | $ | (34,673) | | $ | (25,934) | | $ | (71,264) | | $ | (78,037) |
| (1) | This category is exclusive of non-cash stock-based compensation and severance expense. |
| (2) | Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations. |
|